|LETTER TO THE EDITOR
|Year : 2022 | Volume
| Issue : 7 | Page : 127-128
Expenditure for vaccination and expected gain from COVID-19 vaccine: A situation analysis
Beuy Joob1, Viroj Wiwanitkit2
1 Private Academic Consultant, Bangkok, Thailand
2 Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India; Department of Biological Science, Joseph Ayobabalola University, Ikeji-Arakeji, Nigerai; Department of Tropical Medicine, Hainan Medical University, Haikou, China; Department of Medical Science, Faculty of Medicine, University of Nis, Nis, Serbia
|Date of Submission||22-Feb-2021|
|Date of Decision||04-Apr-2021|
|Date of Acceptance||04-May-2021|
|Date of Web Publication||03-Feb-2022|
Private Academic Consultant, Bangkok
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Joob B, Wiwanitkit V. Expenditure for vaccination and expected gain from COVID-19 vaccine: A situation analysis. Med J DY Patil Vidyapeeth 2022;15, Suppl S1:127-8
|How to cite this URL:|
Joob B, Wiwanitkit V. Expenditure for vaccination and expected gain from COVID-19 vaccine: A situation analysis. Med J DY Patil Vidyapeeth [serial online] 2022 [cited 2022 Sep 27];15, Suppl S1:127-8. Available from: https://www.mjdrdypv.org/text.asp?2022/15/7/127/337212
COVID-19 vaccine is the hope for controlling of COVID-19. There are many new vaccines with different cost-effectiveness. At present, the COVID-19 vaccination is already used in several territories around the world. Israel is a territory that vaccination has been implemented since 2020 and there are the much available data on postvaccination situation comparing to other areas of the world. About 9.3 million people in Israel have already been vaccinated at the end of 2020. The local data from Israel show that the vaccinated people had a significant decrease of incidence of COVID-19 up to 33% at 2 weeks after vaccination. The data on the protection rate from Israel lead to the hope for successful COVID-19 control by vaccine.
In each nation, it is necessary to have a good preparation for the implementation of COVID-19 vaccination. The plan for budgeting is required. Here, the authors perform an analysis to compare the expenditure for vaccination and expected gain from COVID-19 vaccine. The basic parameters for the analysis include (a) incidence of COVID-19; (b) protection rate induced by COVID-19 vaccine, which is hereby referred to the recent report from Israel; (c) the data on cost for COVID-19 patient treatment; and (d) cost of COVID-19 vaccine, which is assigned as the unit price for all required dosages to complete vaccination.
For the analysis in this study, the incidence of COVID-19 in the previous study by Reese et al. on estimation of incidence of the disease is referred to. According to referenced report by Reese et al., the infections were detected in 52.9 from approximately 328.46 million population giving incidence equal to 16.11% (13.64% asymptomatic and 2.47% symptomatic illnesses). Regarding the cost of COVID-19 patient treatment, the cost will incur only the patient is symptomatic and Bartsch et al. reported from a study in the USA that the cost for a single symptomatic COVID-19 case therapy is 3045 USD. Here, the situation analysis on expenditure for vaccination and expected gain from COVID-19 vaccine comparing between with and without vaccination is done. The result from situation analysis is presented in [Table 1].
|Table 1: Situation analysis on expenditure for vaccination and expected gain from COVID-19 vaccine*|
Click here to view
Based on the situation analysis based on 1,000,000 population, the alternatives with and without COVID-19 vaccination, the net required payment will be equal to 318,313,000 and 415,338,000 USD. There is a gain from using COVID-19 vaccination. The expected gain will equal to 97,025,000 USD per 1,000,000 population. This can confirm that the vaccination is a useful public health manipulation policy that should be implemented. Regarding limitation, the present study is based on the primary data. The completeness of primary data cannot be controlled. Additionally, the present analysis is based on record data. The assumption from this retrospective analysis can reflect the past situation. In the present day, there is a rapid change of situation. The occurrence of the new SARS CoV2 strain might significantly affect the incidence and the expected gain from vaccination might be changed. Since the present study is based on a situation analysis on a single setting, the data might be limited for generalization to other settings. Further calculation for assessment based on situations in different settings is recommended.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Sookaromdee P, Wiwanitkit V. New COVID-19 vaccines, its cost and shelf life: A cost effectiveness analysis. Arch Med Res 2021;52:453.
Rosen B, Waitzberg R, Israeli A. Israel's rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res 2021;10:6.
Mahase E. COVID-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected. BMJ 2021;372:n217.
Reese H, Iuliano AD, Patel NN, Garg S, Kim L, Silk BJ, et al.
Estimated incidence of COVID-19 illness and hospitalization–United States, February-September, 2020. Clin Infect Dis 2020;Clin Infect Dis 2021;72:e1010-e17.
Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund SS, et al.
The potential health care costs and resource use associated with COVID-19 in the United States. Health Aff (Millwood) 2020;39:927-35.